Skip to main content
Device Global Header

Subscribe
or Renew

Advanced Search

This article is available to subscribers. Subscribe now. Already have an account? Sign in

Perspective

Brazil’s Fight against Hepatitis C — Universalism, Local Production, and Patents

List of authors.
  • Elize M. da Fonseca, Ph.D.,
  • Kenneth Shadlen, Ph.D.,
  • and Francisco I. Bastos, M.D., Ph.D.

Brazil’s strategy for addressing hepatitis C, which combines evidence-based treatment protocols and innovative initiatives for local production of generic direct-acting antiviral drugs, needs to be considered in light of ongoing conflicts over pharmaceutical patents.

Continue reading this article

Select an option below:

Create your account to get 2 free subscriber-only articles each month.

Get Free Access Now Subscribe For Full Access

Already have an account?

Sign In

Print subscriber?

Activate your online access.

Funding and Disclosures

Disclosure forms provided by the authors are available at NEJM.org.

Author Affiliations

From the Department of Public Administration, São Paulo Business School, São Paulo (E.M.F.), and the Oswaldo Cruz Foundation, Rio de Janeiro (F.I.B.) — both in Brazil; the Center for Latin American Studies, University of California, Berkeley, Berkeley (E.M.F.); and the Department of International Development, London School of Economics and Political Science, London (K.S.). Data collection for this article was funded under the auspices of the São Paulo Research Foundation.

Print Subscriber? Activate your online access.